According to Amsbio, the US Food and Drug Administration's (FDA) approval of Chimeric Antigen Receptor (CAR) T-cells for the treatment of leukemia and lymphoma has created a demand for the technology in research.
A spokesperson for Amsbio told us that, because of the growth in research for the therapeutic uses of CAR T-cells, “Amsbio has a growing list (e.g. BCMA, CD123, PMSA) of experimental cell lines, recombinant proteins, and screening services to advance the search for new CAR T-cell therapies.”
The spokesperson explained that the first FDA approved treatments for CAR-T were cells directed against B cell protein CD19 targets. This approval led to research identifying additional targets for blood cancers and solid tumors.
Each cell line added to Amsbio’s offering was selected because of the different levels of protein in the cell lines to mimic different stages of cancer target cells protein expression.
Amsbio’s experimental cell lines include stable CHO recombinant cell lines, which can be used to express full-length human CD123, PSMA, and ICOSL. Each new clonal cell line was selected for different levels of expression to mimic different stages of cancer target cells with varying levels of CD123, PSMA, and ICOSL.
